Incyte reports positive PhI/II results; Bionovo gets relisted on NASDAQ;

@FierceBiotech: CEO: Roche, Genentech R&D won't merge. Story | Follow @FierceBiotech

@JohnCFierce: Boston Globe picked up on the big concentration of Fierce 15 companies in Boston. Story | Follow @JohnCFierce

> NASDAQ has informed women's health company Bionovo that it has regained compliance with the $1.00 minimum bid price. Bionovo release

> Incyte's drug INCB18424 for myelofibrosis eased symptoms of the disease in a study of 153 patients. If approved the drug, which is licensed by Novartis, would be the first treatment for the bone marrow disorder. Report

> Trading of Alkermes' shares was halted as an FDA expert panel reviews the company's sNDA for Vivitrol (extended-release injectable suspension) for opioid dependence. Alkermes release

> Immune Network plans to buy an oral vaccine technology platform from Immunitor. Immune Network release

And Finally... Duke University have discovered a gene responsible for nearsightedness in Caucasians. Report

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.